Jefferies Group Weighs in on AstraZeneca’s FY2018 Earnings (AZN)

AstraZeneca (NYSE:AZN) – Research analysts at Jefferies Group cut their FY2018 earnings estimates for AstraZeneca in a research report issued to clients and investors on Friday, April 13th. Jefferies Group analyst I. Hilliker now anticipates that the company will post earnings of $1.67 per share for the year, down from their prior estimate of $1.70. Jefferies Group currently has a “Buy” rating and a $36.70 price target on the stock.

How to Become a New Pot Stock Millionaire

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. During the same quarter last year, the business posted $1.21 EPS. AstraZeneca’s revenue for the quarter was up 3.4% on a year-over-year basis.

AZN has been the topic of several other research reports. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Leerink Swann raised their price objective on AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a report on Tuesday, February 6th. BMO Capital Markets set a $40.00 price objective on AstraZeneca and gave the company a “buy” rating in a report on Tuesday, February 20th. Finally, JPMorgan Chase raised AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $38.12.

NYSE AZN opened at $36.32 on Monday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. AstraZeneca has a twelve month low of $28.43 and a twelve month high of $36.75. The firm has a market cap of $92,096.10, a P/E ratio of 8.49, a PEG ratio of 1.85 and a beta of 0.62.

The business also recently announced a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were issued a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date of this dividend was Thursday, February 15th. AstraZeneca’s payout ratio is presently 32.01%.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Commerce Bank lifted its holdings in AstraZeneca by 14.7% during the 4th quarter. Commerce Bank now owns 11,548 shares of the company’s stock worth $400,000 after buying an additional 1,480 shares during the period. M&T Bank Corp lifted its holdings in AstraZeneca by 0.5% during the 4th quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock worth $11,003,000 after buying an additional 1,676 shares during the period. TIAA FSB lifted its holdings in AstraZeneca by 6.7% during the 4th quarter. TIAA FSB now owns 27,087 shares of the company’s stock worth $940,000 after buying an additional 1,692 shares during the period. First Allied Advisory Services Inc. lifted its holdings in AstraZeneca by 7.6% during the 4th quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock worth $825,000 after buying an additional 1,694 shares during the period. Finally, Logan Capital Management Inc. lifted its holdings in AstraZeneca by 7.0% during the 4th quarter. Logan Capital Management Inc. now owns 26,040 shares of the company’s stock worth $904,000 after buying an additional 1,710 shares during the period. 15.14% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Jefferies Group Weighs in on AstraZeneca’s FY2018 Earnings (AZN)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/04/16/jefferies-group-weighs-in-on-astrazenecas-fy2018-earnings-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply